Funding
← Back to your selection

Sofinnova Partners

Activity from announced rounds

Activity in this selectionFrance · Oct 12, 2026 · Jan 1, 2026
Rounds participated in
4
Confirmed lead rounds
1
3 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$282.6M
4 disclosed · full round size, not this investor’s share

By stage

Series A2
Seed1
Undisclosed1

By primary sector

Biotech2
AI1
Healthtech1

By country

France4

Rounds

4 in this selection
HighLife

HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.

€80MFinancing round
Lead
Bionyra Pharma

Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases.

$165MSeries A
Role not disclosed
Signadori Bio

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

Role not disclosed
BrightHeart

BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening.

€11MSeries A
Role not disclosed